ViewPoint Therapeutics Competitors and Similar CompaniesClear all
ViewPoint Therapeutics's competitors and similar companies include Molecular Partners, Brii Biosciences, Y-mAbs Therapeutics and Prevail Therapeutics.
 ViewPoint Therapeutics ViewPoint Therapeutics is a biotechnology company which develops treatments for diseases of protein misfolding, including cataracts. |  Molecular Partners Molecular Partners is a company that develops biopharmaceutical products for serious diseases. |  Brii Biosciences Brii Biosciences researches and develops medicines for the treatment of chronic illnesses with significant burdens, including infectious diseases, liver and lung diseases, and other illnesses. |  Y-mAbs Therapeutics Y-mAbs Therapeutics is a clinical-stage biopharmaceutical company developing novel antibody therapeutics for oncology targets. |  Prevail Therapeutics Prevail Therapeutics is a biotech company that is developing therapeutics for neurodegenerative disorders, such as Parkinson's disease. | |
Founding Date | Founding Date 2014 | Founding Date 2004 | Founding Date 2018 | Founding Date 2014 | Founding Date 2017 |
Type | Type Private | Type Public | Type Private | Type Public | Type Public |
Tags | |||||
Locations | Locations San Mateo, US HQ San Francisco, US | Locations Zürich-Schlieren, CH HQ Cambridge, US Concord, US | Locations CN HQ Beijing, CN Durham, US San Francisco, US San Mateo, US | Locations New York, US HQ Copenhagen, DK Nutley, US | Locations New York, US HQ |
Employees | Employees 1 | Employees 158 | Employees 8510% decrease | Employees 3239% increase | Employees 489% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 657 m | Valuation ($) 787.7 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $87.7m (FY, 2024) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods $15m (FY, 2024) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit $72.7m (FY, 2024) | Gross profit N/A |
Net income | Net income N/A | Net income (CHF61.7m) (FY, 2025) | Net income N/A | Net income ($29.7m) (FY, 2024) | Net income ($63.2m) (FY, 2019) |
Funding | |||||
Latest funding round | Latest funding round $ 35m (about 8 years ago) | Latest funding round N/A | Latest funding round $ 155m (about 5 years ago) | Latest funding round N/A | Latest funding round N/A |
Total funding raised | Total funding raised $ 39m | Total funding raised N/A | Total funding raised $ 415m | Total funding raised $ 80m | Total funding raised $ 125m |
For sources of this data, please see the company profile
View Company Profiles
Molecular Partners
HQ
Zürich-Schlieren, CH
Employees
158
Molecular Partners is a company that develops biopharmaceutical products for serious diseases.
View companyBrii Biosciences
HQ
CN
Employees
85↓ 10% decrease
Brii Biosciences researches and develops medicines for the treatment of chronic illnesses with significant burdens, including infectious diseases, liver and lung diseases, and other illnesses.
View companyY-mAbs Therapeutics
HQ
New York, US
Employees
32↑ 39% increase
Y-mAbs Therapeutics is a clinical-stage biopharmaceutical company developing novel antibody therapeutics for oncology targets.
View companyPrevail Therapeutics
HQ
New York, US
Employees
48↑ 9% increase
Prevail Therapeutics is a biotech company that is developing therapeutics for neurodegenerative disorders, such as Parkinson's disease.
View company